IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Imatinib (Primary) ; Hydroxycarbamide
- Indications Meningioma
- Focus Therapeutic Use
- 23 May 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 02 May 2012 Planned number of patients changed from 76 to 80 as reported by European Clinical Trials Database.
- 07 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History